复星医药：子公司朝晖药业”酮洛芬贴剂“获临床试验批准

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for the drug Ketoprofen patch in China [1] - The drug is primarily intended for pain relief and anti-inflammatory treatment for conditions such as low back pain, osteoarthritis, shoulder periarthritis, tendonitis, and rheumatoid arthritis [1] - As of October 2025, the cumulative R&D investment for this drug by the group is approximately RMB 960,000 (unaudited) [1] Group 2 - According to IQVIA CHPA data, the sales revenue for Ketoprofen formulations in China is projected to be approximately RMB 91.16 million in 2024 [1]